Horizon Therapeutics [HZNP] vs Eli Lilly and [LLY] Detailed Stock Comparison

Horizon Therapeutics Plc

NASDAQ
Loading...

Eli Lilly and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Horizon Therapeutics Plc wins in 6 metrics, Eli Lilly and Company wins in 11 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Horizon Therapeutics Plc Eli Lilly and Company Better
P/E Ratio (TTM) 61.86 40.09 Eli Lilly and Company
Price-to-Book Ratio 5.01 31.01 Horizon Therapeutics Plc
Debt-to-Equity Ratio 0.48 165.31 Horizon Therapeutics Plc
PEG Ratio -16.29 0.79 Eli Lilly and Company
EV/EBITDA 24.08 26.61 Horizon Therapeutics Plc
Profit Margin (TTM) 74.64% 31.67% Horizon Therapeutics Plc
Operating Margin (TTM) 16.83% 44.90% Eli Lilly and Company
EBITDA Margin (TTM) 16.83% 44.90% Eli Lilly and Company
Return on Equity 10.28% 101.16% Eli Lilly and Company
Return on Assets (TTM) 5.72% 19.42% Eli Lilly and Company
Free Cash Flow (TTM) N/A $5.96B N/A
Dividend Yield N/A 0.60% N/A
1-Year Return -6.82% 38.28% Eli Lilly and Company
Price-to-Sales Ratio (TTM) 7.34 12.63 Horizon Therapeutics Plc
Enterprise Value $26.84B $843.37B Eli Lilly and Company
EV/Revenue Ratio 7.40 12.94 Horizon Therapeutics Plc
Gross Profit Margin (TTM) 76.72% 82.52% Eli Lilly and Company
Revenue per Share (TTM) $16 $73 Eli Lilly and Company
Earnings per Share (Diluted) $2.22 $22.94 Eli Lilly and Company
Beta (Stock Volatility) N/A 0.50 N/A
Short % of Float N/A 0.97% N/A

Horizon Therapeutics Plc vs Eli Lilly and Company Stock Performance Analysis

Loading Price Chart...

HZNP
LLY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics Plc0.00%N/AN/AN/AN/AN/A
Eli Lilly and Company-0.32%-1.72%12.38%14.18%6.32%4.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics Plc-6.82%74.04%9.84%176.66%176.66%176.66%
Eli Lilly and Company38.28%153.07%418.42%1,433.98%2,935.09%1,988.48%

Performance & Financial Health Analysis: Horizon Therapeutics Plc vs Eli Lilly and Company

MetricHZNPLLY
Market Information
Market Cap i$26.63B$821.31B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i19,134,2062,387,476
90 Day Avg. Volume i8,460,6952,777,749
Last Close$116.30$1,129.35
52 Week Range$116.30 - $116.34$623.78 - $1,182.73
% from 52W High-0.03%-4.51%
All-Time High$39.49 (Jul 20, 2015)$1,182.73 (Jun 08, 2026)
% from All-Time High194.50%-4.51%
Growth Metrics
Quarterly Revenue Growth0.14%0.43%
Quarterly Earnings GrowthN/A0.51%
Financial Health
Profit Margin (TTM) i0.75%0.32%
Operating Margin (TTM) i0.17%0.45%
Return on Equity (TTM) i0.10%1.01%
Debt to Equity (MRQ) i0.48165.31
Cash & Liquidity
Book Value per Share (MRQ)$23.22$29.66
Cash per Share (MRQ)N/A$8.14
Operating Cash Flow (TTM) i$1.33B$16.81B
Levered Free Cash Flow (TTM) i$1.81B$1.95B
Dividends
Last 12-Month Dividend Yield iN/A0.60%
Last 12-Month Dividend iN/A$6.23

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics Plc vs Eli Lilly and Company

MetricHZNP (Apr 30, 2025)LLY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i61.8640.09
Forward P/E i20.5521.82
PEG Ratio i-16.290.79
Price to Sales (TTM) i7.3412.63
Price to Book (MRQ) i5.0131.01
Market Capitalization
Market Capitalization i$26.63B$821.31B
Enterprise Value i$26.84B$843.37B
Enterprise Value Metrics
Enterprise to Revenue i7.4012.94
Enterprise to EBITDA i24.0826.61
Risk & Other Metrics
Beta iN/A0.50
Book Value per Share (MRQ) i$23.22$29.66

Financial Statements Comparison: Horizon Therapeutics Plc vs Eli Lilly and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHZNPLLY (2025)
Revenue/Sales iN/A65.18B
Cost of Goods Sold iN/A11.05B
COGS % of Revenue i-17.0%
Gross Profit iN/A54.13B
Gross Margin i-83.0%
Research & Development iN/A13.34B
Operating Income (EBIT) iN/A29.70B
Operating Margin i-45.6%
EBITDA iN/A35.09B
EBITDA Margin i-53.8%
Pre-Tax Income iN/A25.73B
Pre-Tax Income % of Revenue i-39.5%
Income Tax iN/A5.09B
Income Tax % of Revenue i-7.8%
Net Income (Profit) iN/A20.64B
Profit Margin i-31.7%

Balance Sheet & Liquidity Metrics

MetricHZNPLLY (2025)
Cash & Equivalents iN/A7.27B
Total Current Assets iN/A55.63B
Total Current Assets % of Revenue i-85.3%
Total Current Liabilities iN/A35.23B
Total Current Liabilities % of Revenue i-54.0%
Long-Term Debt iN/A40.87B
Long-Term Debt % of Revenue i-62.7%
Total Shareholders Equity iN/A26.54B
Retained Earnings iN/A24.47B
Retained Earnings % of Revenue i-37.5%
Property, Plant & Equipment iN/A13.49B

Cash Flow Statement Comparison

MetricHZNPLLY (2025)
Operating Cash Flow iN/A23.60B
Operating Cash Flow % of Revenue i-36.2%
Capital Expenditures iN/A-7.84B
Free Cash Flow iN/A5.96B
FCF Margin i-9.2%
Debt Repayment iN/A-778.00M
Common Stock Repurchase iN/A-4.11B

Short Interest & Institutional Ownership Analysis

MetricHZNPLLY
Shares Short iN/A7.70M
Short Ratio iN/A2.73
Short % of Float iN/A0.97%
Shares Outstanding i229.00M894.80M
Float Shares iN/A890.99M
% Held by Insiders iN/A0.17%
% Held by Institutions iN/A84.77%
% Held by Public iN/A15.06%

Dividend Analysis & Yield Comparison: Horizon Therapeutics Plc vs Eli Lilly and Company

MetricHZNPLLY
Last 12-Month Dividend iN/A$6.23
Last 12-Month Dividend Yield iN/A0.60%
3-Year Avg Annual Dividend iN/A$5.44
3-Year Avg Dividend Yield iN/A0.18%
3-Year Total Dividends iN/A$16.32
Ex-Dividend DateN/AFeb 13, 2026